Federal Circuit Certifies AbbVie’s Constitutional Challenge in Consolidated Adalimumab IPR Appeals to U.S. Attorney General


As we previously reported, currently pending before the Federal Circuit are consolidated appeals from five final written decisions of the Patent Trial and Appeal Board (Board) in inter partes review (IPR) proceedings finding the claims of AbbVie’s U.S. Patent Nos. 8,889,135, 9,017,680, and 9,073,987 unpatentable for obviousness in view of the prior art.  In its appellate briefs, AbbVie challenges the Board’s rulings on the merits, as well as on constitutionality grounds.

Although the consolidated appeals have been fully briefed for nearly six months, the Federal Circuit still has not scheduled the case for oral argument.  Rather, today, the Federal Circuit issued a sua sponte order staying the appeal and certifying AbbVie’s constitutional challenge to the U.S. Attorney General, with the instruction to inform the Court within 30 days whether the United States intends to intervene in the appeals.  The Court’s order does not express any views on the merits of AbbVie’s constitutional challenge and explains that the Court was required by law to certify the challenge to the Attorney General in response to receiving formal notice from AbbVie of its constitutional challenge.  Below is a summary of these pending appeals.

The IPR Petitions:  In late 2015, Coherus filed an IPR petition against each of the ’135, ’680 and ’987 patents, and Boehringer Ingelheim (BI) filed two IPR petitions against the ’135 patent.

AbbVie’s three challenged patents are generally directed to methods for treating rheumatoid arthritis (RA) by subcutaneous (SC) administration of the antibody D2E7 (i.e., adalimumab) in a total body dose of 40 mg once every 13-15 days (biweekly).  Certain claims of the ’135 patent recite an administration period of at least 24 weeks. The claims of the ’680 patent additionally recite the administration in combination with methotrexate.

In mid-2016, the Board instituted each of these five IPRs: IPR2016-00172 (Coherus re: ’135 patent), IPR2016-00188 (Coherus re: ’680 patent), IPR2016-00189 (Coherus re: ’987 patent), IPR2016-00408 (BI re: ’135 patent), IPR2016-00409 (BI re: ’135 patent).

The Board’s Ruling:  In mid-2017, after the oral hearings of these IPRs, the Board ruled in favor of the petitioners in each of the five proceedings, finding all claims of the ’135 patent, ’680 patent and ’987 patent unpatentable based on obviousness over the prior art.  The Board found that a person of ordinary skill in the art would have been motivated to develop and administer D2E7 according to the claimed regimen, including for a period of at least 24 weeks and in combination with methotrexate, with a reasonable expectation that it would successfully treat RA.  The Board reasoned that the prior art reported clinical trials showing that biweekly 40 mg intravenous (IV) doses of D2E7 were effective in treating RA, that weekly 20, 40 and 80 mg SC doses were effective in treating RA, and that SC administration was comparable to IV administration.  AbbVie tried to defend the patentability of the claims by arguing, among other things, that the prior art taught away from using a 40 mg SC dose, particularly for a period of at least 24 weeks, and that the commercial success of Humira® (adalimumab) constituted a compelling objective indicium of non-obviousness.  The Board, however, found that the prior art did not teach away from the claimed invention and that AbbVie failed to establish a nexus between the alleged commercial success and the claimed dosing regimen.

AbbVie’s Appeal:  In July 2017, AbbVie appealed to the Federal Circuit from the Board’s five unfavorable final written decisions. The five appeals were consolidated later that year, with Federal Circuit Case No. 17-2304 constituting the lead case.

On December 13, 2017, AbbVie filed its opening appellate brief, addressing all of the IPR decisions.  AbbVie contended that the Board’s obviousness determinations were based on legal error because, among other things, the Board (i) relied on hindsight analysis, (ii) improperly shifted the burden of persuasion from the petitioners to AbbVie, (iii) failed to consider the claims as a whole, (iv) applied the wrong legal standard for one obviousness combination, and (v) unconstitutionally subjected the challenged patents to IPR proceedings.

Specifically, AbbVie argued that despite the wide range of possible approaches to treating RA with D2E7 presented by the prior art, the Board arbitrarily focused only on doses at the lowest end of what was disclosed, to the exclusion of other possibilities, “push[ing] beyond the boundaries of anything discussed in the prior art.” According to AbbVie, “[t]he Board improperly relied on hindsight to steer its way through these choices, ignoring more promising alternatives and improperly examining the motivation to achieve the specific combination that AbbVie made rather than a contemporaneous motivation to produce an improved treatment regimen.”

AbbVie also contended that the Board wrongly shifted the burden from the petitioners to AbbVie by discounting evidence that, according to AbbVie, demonstrated a lack of information and uncertainty in the prior art that supported non-obviousness. For example, AbbVie asserted that the Board misinterpreted a prior art reference that purportedly indicated that all RA patients on a 0.5 mg/kg IV dosing regimen (approximately equivalent to a total dose of 40 mg) were either withdrawn or up-dosed during a clinical study, such “that none of the 24 patients receiving 0.5 mg/kg continued that treatment beyond 12 weeks.”  According to AbbVie, these data in the prior art taught away from using the claimed 40 mg dosing regimen, especially for 24 weeks, and the Board was wrong to discount the reference simply because the reference lacked a specific statement that all patients were up-dosed due to ineffectiveness of the regimen as opposed to some other reason.  “Counting that silence against AbbVie was improper,” it argued.  Furthermore, regardless of whether the reference definitively “taught away,” AbbVie argued that the Board erred in its obviousness analysis because it did not “consider the effect that the same uncertainty would have had on a skilled artisan’s motivation to combine and reasonable expectation of success.”

In addition, AbbVie argued that the Board improperly shifted burdens in its analysis of the commercial success of Humira®. AbbVie argued that it was entitled to “a presumption of a nexus between the commercial success of HUMIRA® and the patented invention[,]” and the Board “failed to hold Petitioners to its ‘burden of disproving’ the nexus[,]” instead finding “that the Petitioners had rebutted the presumption merely by injecting uncertainty” into the analysis.

AbbVie additionally contended that the Board failed to view the claims as an integrated whole. According to AbbVie, the Board instead combined references that differed across many parameters, including: treatment interval, method of administration, dose size, and fixed versus patient-specific weight-based dose.

AbbVie further argued that the Board erroneously applied the institution-stage standard (i.e., “a reasonable likelihood of prevailing at trial”) to an alternative prior art combination proffered in one of BI’s IPR petitions, rather than concluding that BI had proved unpatentability at trial based on this combination of references.

Finally, AbbVie argued that reversal was warranted because the Board’s decisions violated Article III of the U.S. Constitution and the Seventh Amendment “because the inter partes review process authorizes an executive branch agency, rather than an Article III court with a jury, to extinguish the private property right in a previously issued patent without the consent of the patent owner.” AbbVie, however, acknowledged that this argument was “foreclosed by circuit precedent,”  but clarified that AbbVie was “preserv[ing] this argument in light of the Supreme Court’s impending decision in Oil States Energy Services LLC v. Greene’s Energy Group, LLC, No. 16-712 (U.S).”  (As discussed below, the Supreme Court issued its decision in Oil States four months later.)

Coherus’ and BI’s Responses:  On March 23, 2018, Coherus and BI each filed responsive appellate briefs.  In their respective briefs, they argued that the Board applied the correct legal analysis and that the Board’s decisions were supported by substantial evidence.

First, Coherus and BI argued that the Board conducted its analysis free from hindsight, correctly applying the burden of proof, and properly accounting for the claims as a whole. For example, they argued that when Board determined that AbbVie failed to show that the prior art taught away or that commercial success did rebut the obviousness of the claims, the Board “simply reject[ed] AbbVie’s own characterization of the art as teaching away,” and did not improperly shift the burden of proof onto AbbVie.

Second, Coherus and BI contended that the Board’s decisions were supported by substantial evidence. Among other things, Coherus and BI argued that the Board was entitled to consider and reject AbbVie’s factual allegations that up-dosing taught away from using the claimed dosing regimen.  In response to AbbVie’s contention that RA patients on the 40 mg dosing regimen were either up-dosed or withdrawn in a prior art clinical trial because it was an ineffective dose, Coherus and BI asserted that multiple prior art references reported the 40 mg regimen as effective, and that mere up-dosing alone did not evidence a lack of efficacy.  Similarly, Coherus and BI argued that substantial evidence supported the Board’s discounting of AbbVie’s evidence of objective indicia of non-obviousness, such as commercial success, for lack of a nexus to the claimed invention.

Regarding AbbVie’s contention that the Board erroneously applied the institution-stage standard to BI’s alternative obviousness combination of references, BI countered that the Board’s recitation of the standard for institution “at one place in its decision” was at worst a “misstatement [that] does not warrant reversal.”  According to BI, the Board recited “the proper standards … throughout the Board’s opinion” and correctly applied those standards in conducting its obviousness analysis, which was “supported by substantial evidence.”

In response to AbbVie’s constitutionality challenge, Coherus and BI noted that even AbbVie had acknowledged that its challenge was foreclosed under then-current circuit precedent, unless it were to be reversed by the Supreme Court in its impending Oil States decision.

The Supreme Court issued its decision in Oil States a few weeks later, on April 24, 2018, holding that IPR proceedings do not violate Article III or the Seventh Amendment of the United States Constitution.  The Court noted, however, that its holding was limited to the precise issues before it and was not foreclosing the possibility of future constitutional challenges.

AbbVie’s Reply:  On May 4, 2018, AbbVie filed a reply brief. AbbVie reiterated, among other things, that up-dosing in prior art clinical trials taught away from using the claimed dosing regimen.  AbbVie further reiterated that the PTAB improperly applied the standard for instituting an IPR.  In response to BI’s assertion that the mistake should be overlooked as a mere typographical error or misstatement, AbbVie contended that the Board could clarify this issue on remand.

With regard to its constitutional challenge, AbbVie noted that while the Supreme Court’s decision in Oil States a couple weeks earlier “rejected a facial challenge to inter partes review under Article III and the Seventh Amendment,” the Supreme Court “went out of its way” to “emphasize the narrowness of its holding” and “le[ave] the door open to challenge the retroactive application of inter partes review.”  Based on that alleged opening, AbbVie argued that it was unconstitutional to subject the three challenged patents to IPR proceedings because they issued from patent applications that were filed before the America Invents Act (AIA) was enacted and established the IPR system.  According to AbbVie, “An inventor pays the price for patent protection when it discloses its invention. The public cannot subsequently change the terms of the bargain, at least not when it comes to something as fundamental as eliminating the traditional role of an Article III court or eroding the safeguards provided by the presumption of validity.” AbbVie concluded that “where a patent is retroactively subject to IPR, the balance shifts and both Article III and due process prohibit such a fundamental change.”

Certification of AbbVie’s Constitutionality Challenge:  On October 17, 2018, AbbVie filed a Notice of Constitutional Challenge pursuant to Federal Rule of Appellate 44(a), which requires a party who questions the constitutionality of a Federal statute on appeal to give written notice to the clerk of court, who must then certify that fact to the U.S. Attorney General.  Although AbbVie alleged that it raised its constitutional challenge in its notice of appeal, docketing statement and briefs to the Court, AbbVie explained that it was filing the separate Notice in light of the Court’s September 26, 2018 proposed new practice note that, if adopted, will require any party making a constitutional challenge in a motion or brief to the Court to provide a separate notice of that challenge before the clerk of court will certify the matter to the Attorney General.

Today, October 31, 2018, the Court responded to AbbVie’s Notice by issuing an order staying the appeals and certifying the fact of AbbVie’s constitutional challenge to the Attorney General.  The Court’s order directs the Attorney General to inform the Court within 30 days (i.e., by November 30, 2018) whether the United States intends to intervene.  The order states that if the United States declines to intervene, the stay will be lifted and the appeals will proceed in the ordinary course (e.g., be scheduled for oral argument).  If, however, the United States elects to intervene, as it did recently in other pending appeals concerning similar constitutionality challenges, the Court’s order provides that the stay will be lifted but AbbVie’s reply brief will be stricken and the United States will have 40 days from such election to file a response brief; AbbVie’s replacement reply brief will then be due no later than 14 days after service of the United States’s response brief.  In short, today’s order has the potential to delay scheduling of oral argument and eventual resolution of the appeals by at least another month and potentially several more months, depending on whether the United States elects to intervene.

Stay tuned to Big Molecule Watch for further developments.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:


Goodwin on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.